logo
  

Coherus Announces Positive Interim Results From Phase 3 Trial On Non-Small Cell Lung Cancer

Coherus BioSciences Inc. (CHRS) and Shanghai Junshi Biosciences Co., Ltd. announced positive interim results from a phase 3 clinical trial, which evaluated toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer or NSCLC.

The interim analysis from the pivotal study "CHOICE-01" (NCT03856411) met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival per RECIST v1.1 compared to chemotherapy alone.

The interim results will be presented on September 13 at IASLC 2021 World Conference on Lung Cancer.

The company expects to pursue registration for toripalimab for a broad array of indications in China, the United States and other markets.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
RELATED NEWS
Follow RTT